First Patient Enrolled in Revita® Wound Care Study


We’re excited to announce the commencement of our second level 1 clinical study for Revita!

This level 1 randomized controlled trial will assess the safety and efficacy of Revita as a wound covering for diabetic foot ulcers (DFUs). Diabetes impacts 30 million people across the United States, and as many as 25% of diabetic patients will develop a DFU within their lifetime.1-2 Without proper treatment, DFUs commonly result in amputation, leaving the patient with a 50% chance of survival. 3-4

As the first placental membrane allograft to capture the complete intact membrane in a shelf-stable format, Revita is uniquely capable of addressing DFUs. Since the product was launched, Revita has shown excellent effectiveness as a wound covering for a broad range of wound types including DFUs. This study will build on that experience and demonstrate broader, clinically validated outcomes.

We are thrilled to have this trial underway and are continuing to invest in high quality outcomes data for the complete portfolio of StimLabs products.

More information on this study can be found press release.

MKTG 19- 004 Rev 01

1. American Diabetes Association. Statistics About Diabetes. 2018 Mar.2. Singh N, Armstrong DG, Lipsky BA. Preventing foot ulcers in patients with diabetes. JAMA2005;293:217–228pmid:1564454.3. Alexiadou, Management of Diabetic Foot Ulcers. 2012 Apr 20.4. Armstrong DG, Wrobel J, Robbins JM. Guest editorial: are diabetes-related wounds and amputations worse than cancer? Int Wound J 2007;4:286–287pmid:18154621

MMPs: A Surprising Ingredient in Healthy Wound Repair

How much do you really know about MMPs? MMPs are often portrayed as the adversary in wound repair and TIMPs are frequently considered the hero. The truth is more complex than this. The proper functioning of each depends on the other and they work together to help create a balanced environment that keeps tissue healthy. Click play for a 10-minute video on the compound roles of these proteins and the ways they work to facilitate tissue restoration.

MKTG18-029 Rev 01

What is Hyaluronic Acid?

By now, most of us have probably heard of hyaluronic acid (HA). Whether as a pain reliever for joints and tendons or a main ingredient in anti-aging serum, hyaluronic acid is widely-recognized as a key molecule found throughout the body.  But what is it that makes HA so unique? How does it work natively and where can it be sourced from? Watch this short video as StimLabs’ scientist, Annelise Roy, gives the lowdown on hyaluronic acid and its versatile functions.

MKTG 18-028 Rev 01

First Patient Enrolled in Revita® Spine Study

We’re excited to announce our first level 1 clinical study for Revita full thickness placental allograft!


This clinical trial will assess the safety and efficacy of Revita placement following lumbar microdiscectomy procedures. Common complications following microdiscectomy procedures include scar tissue formation and reherniation, which are known to cause back and leg pain. Patients with extensive scar tissue are 3.2 times more likely to experience recurrent radicular pain than those with less extensive scarring1.

The use of a barrier membrane, such as Revita, is expected to reduce the rate of occurrence for these types of complications and improve functional outcomes following surgery. The first patient has been enrolled in a 182-patient multi-center randomized controlled single-blinded (patient) trial evaluating the use of Revita as a barrier membrane to reduce these types of complications and improve functional outcomes. More information on this study can be found in the press release.

We are thrilled to have this trial underway, and we are continuing to invest in robust clinical validation of both Revita and Ascent through several case series and large randomized controlled trials.

MKTG 18-020 Rev 01

1. Ross et al,. Association between peridural scar and recurrent radicular pain after lumbar discectomy: magnetic resonance evaluation. ADCON-L European Study Group. AJNR Am J Neuroradiol, January 1998, 19:183–186

Is an MSC a stem cell or a signaling cell?

Over the past few decades, stem cells have become synonymous with regenerative medicine. Stem cells are unspecialized cells that have the capacity for self-renewal and the ability to specialize into different adult cell types. With the dawn of stem cell therapies has come many misconceptions; the most prevalent misconception is that stem cell therapies involve embryonic stem cells. In fact, the majority of stem cell therapies are derived from adult stem cells that are harvested from the bone marrow or fat of adults. These treatments were initially based on the underlying principle that infused stem cells congregate at injured tissue sites, differentiate into the injured tissue type, and replace the injured tissue with new, healthy tissue. 

Mesenchymal stem cells (MSCs) are an adult stem cell type that feature heavily in cell therapies. They are a multipotent cell that can specialize into mesenchymal tissue types (e.g. bone, cartilage, fat). When MSCs were discovered, they were branded as ‘stem cells’ because they exhibited in vitro multipotency capabilities. This discovery made them an attractive therapy option for clinicians. Since then, hundreds of cell therapy studies have been performed with living MSCs infusions. This paradigm has fueled the way regenerative medicine has designed and developed stem cell therapies for over a decade.

But do MSCs work the way we originally thought? 

Read More